We are studying the effects of a new antibody treatment, amivantamab, alone and with chemotherapy for patients with early-stage lung cancer. This research aims to see if it helps before surgery and how it affects tumor characteristics.
Health conditions and diseases that the clinical trial is designed to study and treat.
Non-Small Cell Lung Cancer (NSCLC) with an oncogenic EGFR mutation is a type of lung cancer that is characterized by specific genetic changes, often leading to abnormal cell growth in the lungs. This condition typically affects stages I B, II, and selected stages III A.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
